Alejandro Munoz, MD
Endocrinology, Diabetes & Metabolism · Fort Collins, CONPI 1568639391
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,523 of the $2,123 with a category attached, or 71.7%. 12 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 40.3% of the total. Reporting peaked in 2019 at $1,067 and has fallen 98.1% since, to $20 in 2025.
Across 21 payments — averaging $101.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$856
- Insulet Corporation$332
- Medtronic$225
- Mannkind Corporation$126
- AstraZeneca$126
- Novo Nordisk$123
- plus $335 from 6 others
What the payments were for
- Travel & lodging$56126%
- Food & beverage$1,52372%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 6 | $856 |
| Insulet Corporation | 3 | $332 |
| Medtronic | 2 | $225 |
| Mannkind Corporation | 1 | $126 |
| AstraZeneca | 1 | $126 |
| Novo Nordisk | 1 | $123 |
| BETA Bionics, Inc. | 1 | $83 |
| Amgen | 1 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Lilly USA, LLC | 2 | $42 |
| Abbott | 1 | $40 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$663
- Omnipod$237
- MINIMED 780G$225
- AFREZZA$126
- FARXIGA$126
- Tresiba$123
How this compares
$2,123 in reported general payments places this provider in the 60th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 659 | $821,722 |
| OzempicSemaglutide | 484 | $709,931 |
| JardianceEmpagliflozin | 264 | $285,821 |
| TrulicityDulaglutide | 125 | $204,945 |
| Tresiba Flextouch U-100Insulin Degludec | 236 | $133,925 |
| FarxigaDapagliflozin Propanediol | 77 | $85,921 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $85,460 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 59 | $79,380 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 73 | $73,220 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $57,778 |
| FiaspInsulin Aspart (Niacinamide) | 45 | $55,082 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 25 | $52,541 |
| Humalog Kwikpen U-200Insulin Lispro | 33 | $51,909 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 232 | $39,384 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $39,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $42 | $1,039,941843 claims |
| Novo NordiskOzempic, Fiasp, Novolog, Tresiba | $123 | $782,539600 claims |
| AstraZenecaFarxiga, Crestor | $126 | $89,34089 claims |
| Sanofi-aventis U.S. LLCLantus | $72 | $7,16133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Fort Collins
- Polina KaloyanovaFort Collins$2K
- Barbara WidomFort Collins$2K
- Meriam IzonFort Collins$1K
- Darin OlsonFort Collins$963
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.